Novartis logo.
RLT Institute

Welcome to the forefront of modern cancer treatment

The Novartis RLT Institute

Your expertise and your team are the keys to providing patients access to radioligand therapy (RLT) and we are here to support you

The future of precision oncology

RLT is an innovative approach to cancer treatment that delivers targeted ionizing radiation directly to tumor cells, regardless of where they are in the body. Experimenting with the building blocks of radioligands—combining different radioisotopes and targeting molecules—to develop new RLTs may lead to treatments for a broad range of cancers. Novartis is committed to pursuing the potential of RLT.

Explore tools and practical considerations for integrating our RLTs into your practice

A 3-part illustration including supportive architectural pillars, radioligand molecules binding to cancer cells, and a multidisciplinary care team with a patient.
Foundations of theranostics

Explore the science behind RLT, including its role as an emerging pillar in cancer treatment, as well as key safety principles

An illustration depicting elements of licensing and safety for radioligand therapy programs.
Licensing and safety

Review important aspects to obtain or amend a radioactive materials (RAM) license for medical use, including key individuals and components of the application

An illustration depicting radioligand therapy facilities and equipment, including radiation warning signs, a treatment chair, and space schematics.
Facilities and equipment

Understand the considerations in setting up facilities and equipment required to provide RLT

A 3-part illustration depicting a radioactivity measurement device and radioactive-labeled package, a patient receiving radioligand therapy, and a male health care professional disposing of waste in a radioactivelabeled waste bin.
Providing and administering RLT

Discover processes for safely handling RAM, administering RLT, and optimizing patient care

An icon of a question mark.

FAQs and resources

Find answers to common questions and access key resources to support health care providers and clinic staff in delivering or preparing for RLT

The information herein is intended to assist practitioners in providing appropriate care for patients when using radiopharmaceuticals. This information is not intended to establish, nor should it be used to establish, a legal standard of care. It is important to adhere to all applicable standards when handling and administering radiopharmaceuticals. Institutions are responsible for ensuring their compliance with all laws and regulations by establishing their own policies, procedures, and guidance. Novartis Pharmaceuticals Corporation does not endorse or recommend any specific course of action, or any third-party organization referenced herein.


Reference: Sgouros G, Bodei L, McDevitt MR, et al. Nat Rev Drug Discov. 2020;19:589-608. doi:10.1038/s41573-020-0073-9.